Jump to main content

A look inside our labs

Welcome to the Research & Development Team in Marburg

Innovation is in our genes and is the driving force behind everything we do. Our team of over 1,700 R&D experts worldwide is committed to developing and launching new treatments that make a significant medical contribution and can save lives.

Research & Development

Introduction to the department

Our scientists have gained worldwide recognition for their contribution to the development of new medicines that have the potential to significantly improve patient quality of life.

Watch video

Driving innovation and growth

CSL Behring focuses on five therapeutic areas for continuous development: Immunology and Neurology, Hematology and Coagulation Disorders, Transplantation, Respiratory, Cardiovascular and Metabolic Diseases. The drugs developed from these five therapeutic areas are manufactured on different technology platforms: plasma fractionation, recombinant technology and gene and cell therapy.

Marburg is CSL Behring’s largest R&D site, with over 400 scientists and employees across the R&D functions, such as Research, Recombinant and Plasma Product Development, Clinical Development, Global Pathogen Safety, Pharmacovigilance, Project Management and Drug Approval, combined with the Commercial and Production departments on one site.

We appreciate your interest in our work.

We hope you enjoy discovering our company and what we do!



CSL Behring’s research department explores and develops novel treatments for people with rare and serious diseases. We generate and characterize recombinant proteins for in vitro and in vivo analyses and plan and support preclinical pharmacological and toxicological studies.


Plasma Product Development (PPD)

We develop novel plasma proteins with improved efficacy and greater user-friendliness for people with rare or serious diseases. Our activities focus on process development and technical implementation.


Recombinant Product Development (RPD)

The team develops and characterizes new recombinant proteins, such as in the development of monoclonal antibodies for the treatment of inflammatory diseases, hereditary angioedema or lipid metabolism disorders.

Bjorn Keiner

Global Pathogen Safety (GPS)

Also known as “virology”, this team ensures that the production processes for our drugs significantly reduce any potentially contaminating viruses. The department develops and evaluates state-of-the-art process steps that remove or inactivate viruses and other pathogens.

Virus with RNA Molecule

Viral Vector Process Development

In our viral vector process development lab, we express, purify, and characterize lentiviruses.